Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer

BACKGROUND: Osimertinib demonstrated promising efficacy for refractory leptomeningeal metastases (LM) in preclinical data and a clinical study at 160 mg, but there is limited data for the standard 80 mg dose. METHODS: T790M-positive patients with suspected LM after classical epidermal growth factor...

Descripción completa

Detalles Bibliográficos
Autores principales: Nanjo, Shigeki, Hata, Akito, Okuda, Chiyuki, Kaji, Reiko, Okada, Hideaki, Tamura, Daisuke, Irie, Kei, Okada, Hiroshi, Fukushima, Shoji, Katakami, Nobuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2018
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765232/
https://www.ncbi.nlm.nih.gov/pubmed/29190637
http://dx.doi.org/10.1038/bjc.2017.394

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765232/
https://www.ncbi.nlm.nih.gov/pubmed/29190637
http://dx.doi.org/10.1038/bjc.2017.394

Ejemplares similares